Drugs / LK101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06054932 | Sep 2023 → Dec 2025 | neoplasm | Beijing Likang Life Science and Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05886439 | May 2023 → May 2027 expected | lung cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LK101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886439 ↗ |
| Modality | Vaccine | “personlized neoantigen pulsed DC vaccine” NCT05886439 ↗ |